Endpoints News 生物医药· Kyle LaHucik·· 2026-10-01AI 评分27
Eli Lilly 终止合作,Foghorn 裁员 40%
Lilly pulls back from Foghorn's synthetic lethality work as biotech sheds 40% of staff
AI 导读
Eli Lilly 宣布放弃 Foghorn Therapeutics 的“合成致死”药物开发项目,Foghorn 因此将裁员 40%。该决定导致这家生物技术公司大幅缩减人员,凸显了双方在药物研发路径上的最终分道扬镳。
正文
Eli Lilly is walking away from Foghorn Therapeutics’ “synthetic lethality” drug development, and the small biotech is reducing its headcount by 40% as a result …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news